

Contents lists available at ScienceDirect

Preventive Medicine Reports



journal homepage: www.elsevier.com/locate/pmedr

A comparative analysis of Postpartum Hemorrhage incidence and influencing factors between nulliparous and multiparous women in Hunan Province, China: A multicenter retrospective cohort study

Prince L. Bestman^{a,*}, Musa Nget^b, Edwina M. Kolleh^b, Eva Moeng^a, Tesfit Brhane^b, Jun qun Fang^{c,*}, Jiayou Luo^{a,*}

^a Department of Maternal and Children Health, Xiangya School of Public Health, Central South University, Changsha 410078, Hunan Province, China

^b Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, Hunan, China

^c Department of Health Care, Hunan Provincial Maternal and Child Health Care Hospital, Changsha 410078, Hunan, China

ARTICLE INFO

Keywords: Incidence Influencing factors Postpartum hemorrhage Nulliparous Multiparous

ABSTRACT

Objectives: Postpartum hemorrhage (PPH) is a common cause of maternal death worldwide, but data on PPH incidence and influencing factors for nulliparous and multiparous women is scarce. So, the study aimed to assess the differences in PPH incidence and influencing factors between nulliparous and multiparous women.

Methods: A multicenter retrospective cohort study was conducted among women who gave birth at \geq 28 weeks of gestation in Hunan Province, China, from January 2017 to December 2018. Logistic regression assessed PPH-influencing factors, and the receiver operating characteristic curve (ROC curve) assessed the predictive performance of identified factors.

Results: A total of 144,845 postpartum women were included in the study. The incidence of PPH (blood loss \geq 500 ml) was 2.1 % and 1.7 % for nulliparous and multiparous women, respectively. Among the nulliparous and multiparous women, similar influencing factors of PPH included erythrocyte suspension transfusion before childbirth, anemia, soft-birth canal avulsion, Cesarean-section, placenta abruption, and general anesthesia administration before birth. Thrombophlebitis was associated [aOR 18.46(1.67–20.31)] with PPH among only the nulliparous women, while instrument-assisted birth [aOR 1.95(1.16–3.28)] and gestational hypertension [aOR 1.57(1.13–2.19)] were associated with PPH among only the multiparous women. The areas under the ROC-curve for the overall-cohort, nulliparous, and multiparous groups were [0.829(0.821–0.838)], [0.828 (0.815–0.840)] and [0.833(0.822–0.844)], respectively.

Conclusion: PPH incidence is higher among nulliparous women than among multiparous women, but influencing factors vary relatively by parity. The study findings provide new insights into the use of different approaches to PPH prevention for nulliparous and multiparous women in clinical practice.

1. Introduction

Postpartum hemorrhage (PPH) is defined as blood loss of 500 ml or more within 24 h following birth, and severe PPH is defined as blood loss of 1000 ml or more within 24 h following childbirth (Who, 2009). PPH is a common cause of maternal mortality that accounts for about onequarter (25 %) of all maternal deaths globally (Geller et al.,2006; Knight M,Callaghan WM,Berg C,et al., Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth.,2009;Say et al.,2014). According to the World Health Organization's (WHO) and existing research, 14 million women develop PPH annually, 127,000 die, and half of these deaths occur in Africa and Asia (Sosa et al., 2009; Who, 2012; Khan et al., 2006; Hogan et al., 2010). Despite recent advances in obstetric emergency care and preventive measures in China, PPH remains the leading cause of maternal death (32 %) (Feng et al., 2010).

Globally, there is growing public concern over the rising incidence of PPH (blood loss \geq 500 ml), with estimates ranging from 1.47 to 18 % among women of mixed parity in published studies (Magann et al.,

* Corresponding authors. *E-mail addresses:* plbestman@gmail.com (P.L. Bestman), jufang3497@163.com (J. Fang), jiayouluo@126.com (J. Luo).

https://doi.org/10.1016/j.pmedr.2023.102580

Received 13 July 2023; Received in revised form 22 December 2023; Accepted 23 December 2023 Available online 10 January 2024

2211-3355/© 2023 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2005; Devine, 2009; Magann et al., 2005). Even though nulliparous and multiparous women make up a large part of the birthing population, there is limited information about the incidence of PPH in these women's groups. Only a few nulliparous studies (Bais et al., 2004; Govindappagari et al., 2020) assessed PPH incidence, with reported estimates ranging from 4.2 % to 19.0 %, but no study has assessed PPH incidence in multiparous women.

Although there are studies (Li et al., 2021; Liu et al., 2021;21 (1):332.; Xu et al., 2018; Wei et al., 2020) reporting PPH incidence among the general birthing population in China, with estimates ranging from 0.81 % to 15.4 %, no study has assessed the differences in PPH incidence for nulliparous and multiparous women. Although PPH accounts for the vast majority of maternal deaths worldwide, most PPHassociated maternal deaths are preventable if influencing factors are identified early and prompt measures are implemented (Sosa et al., 2009; Who, 2012; Khan et al., 2006). Therefore, with nulliparous and multiparous women making up a large part of the birthing population, it is essential to assess factors influencing PPH among these women's groups to help prevent PPH and its associated complications. Accordingly, several population-based studies from Latin America, Australia, the Netherlands, and the United States have assessed factors influencing PPH among women of mixed parity (Sosa et al., 2009; Magann et al., 2005; Ford et al., 2007; Chang et al., 2011; Kramer et al., 2013). However, only a few studies (Bais et al., 2004; Dionne MD, Deneux-Tharaux C, Dupont C,et al., Duration of Expulsive Efforts and Risk of Postpartum Hemorrhage in Nulliparous Women: A Population-Based Study. PLoS One.,2015;Govindappagari et al.,2020) have assessed factors influencing PPH among nulliparous women; no study has assessed factors influencing PPH among multiparous women. The few nulliparous studies reported relatively different influencing factors of PPH (including abnormal third-stage labor, expulsive efforts, mild thrombocytopenia, epidural analgesia, and prophylactic postpartum oxytocin administration), assessed few risk variables, and used a smaller sample size compared to our current study. In China, there are studies (Li et al., 2021; Liu et al., 2021;21(1):332.; Xu et al., 2018; Wei et al., 2020) reporting a few similar PPH influencing factors (including macrosomia, placenta previa and abruption) and some different influencing factors (including obesity (Li et al., 2021), conception through in vitro fertilization, maternal age < 18 years (Liu et al., 2021;21(1):332.), repeated cesarean section (Xu et al., 2018), and lateral perineotomy (Wei et al., 2020) of PPH among the general birthing population. However, there is no information on whether or not these influencing factors are the same or different for nulliparous and multiparous women.

As a result, this study aimed to assess the differences in PPH incidence and influencing factors for nulliparous and multiparous women for the first time to provide a scientific basis for using different approaches to preventing PPH in these women's groups.

2. Methods

2.1. Data Sources, Inclusion, and exclusion criteria

The multicenter hospital-based retrospective cohort study collected data from medical records at 18 randomly selected health facilities (5 general hospitals and 13 maternal-child healthcare hospitals) within Hunan Province, South China. This study was performed following the Principles of the Declaration of Helsinki. Our study followed the institution's guidelines for protection of human subjects concerning their safety and privacy. Ethical approval was granted by the Ethics and Research Committee of the Xiangya School of Public Health, Central South University (No. XYGW – 2023–52).

The sum of 144,845 pregnant women admitted to hospitals in Hunan Province, South China, from January 1, 2017 to December 31, 2018, who gave birth at \geq 28 weeks of gestation were included into the study, while those without data on the exact gestational age at birth were excluded. The study data was collected using China's validated Annex 1

Critical Maternal Surveillance Questionnaire (Appendix A). Complete medical information for each birth, including maternal sociodemographic and obstetric factors (including maternal age, marital status, education, gravidity, type of pregnancy, place of birth, antenatal care visits, mode of birth, gestational age, and birth weight) were assessed. From the time of admission until the time of discharge, we assessed comorbidities or complications that occurred. These included anemia, diabetes, hepatopathy, gestational hypertension, blood clot formation disorder, low platelet count(<50,000 µl), systemic infection, HELLP syndrome, puerperal/postpartum infection, pre-eclampsia/eclampsia, placenta previa and abruption, soft birth canal avulsion, and thrombophlebitis. We also evaluated medical measures, including hysterectomy, administration of general anesthesia before childbirth, administration of magnesium sulfate before birth, erythrocyte suspension before delivery, and platelet transfusion. We categorized comorbidities or complications during pregnancy and childbirth, as well as the medical measure variables, as "yes" or "no.".

2.2. Definitions

This study's primary outcome was PPH, defined as greater than or equal to 500 ml of blood loss after childbirth. Using WHO guidelines. PPH was classified as moderate (for blood loss of 500–999 ml following birth) or severe (for blood loss of 1000 ml or more following birth) (Who, 2009). Following the WHO recommendations, anemia was diagnosed in pregnancy when the concentration of hemoglobin was less than 110 g/L (<11 g/dL) (Shi et al., 2022;5(2):e2147046.). The diagnosis of diabetes followed the International Association of Diabetes and Pregnancy Study Group (IADPSG) 2010 criteria (Association and of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, 2010), while the diagnosis of hypertensive disease of pregnancy (gestational hypertension and preeclampsia/eclampsia) followed the 2009 recommendation of the International Society for the Study of Hypertension in Pregnancy (ISSHP) (Brown et al., 2001;20(1):IX-XIV.). The diagnosis of hepatopathy was made following the recommendations in the American College of Gastroenterology's (ACG) Clinical Guidelines for Liver Disease in Pregnancy (Tran et al., 2016). Placenta previa was diagnosed using ultrasonography and magnetic resonance imaging (MRI), showing that the placental margin reached the internal cervical orifice after 28 weeks of gestation. Furthermore, placental abruption was diagnosed based on positive signs of vaginal bleeding and uterine tachysystole, which indicated partial or complete placenta detachment from the uterus after 20 weeks of gestation but before delivery. Soft birth canal avulsion refers to obstetric trauma that occurs during labor and delivery, affecting the birth canal and soft tissue. Amniotic fluid embolism was defined as a severe but rare obstetric emergency in which amniotic fluid enters the bloodstream of a pregnant mother) (McDonnell et al., 2015). In our study, thrombophlebitis (a condition characterized by blood clot formation in a vein that causes inflammation and pain) included deep vein thrombosis (DVT) of the legs and pelvis. Diagnosing thrombophlebitis relies on a combination of clinical evaluation and diagnostic tests. If an initial Doppler ultrasound (a noninvasive method that uses sound waves to visualize blood flow) was negative, additional investigation, including serial compression ultrasound or magnetic resonance venography (which employs magnetic resonance imaging technology to provide detailed vein images, detect clots or obstructions, and assess vein-related conditions), was performed for the diagnosis of thrombophlebitis in pregnancy. The diagnostic procedures followed the American Society of Hematology 2018 guidelines for managing venous thromboembolism in pregnancy (Bates et al., 2018).

2.3. Statistical analysis

A descriptive statistic was used to calculate the frequency, means, percentages, and incidence of PPH in the study. A Multivariate logistic regression was performed to identify PPH-influencing factors for

Table 1

Sociodemographic and Obstetric Characteristics for Nulliparous and Multiparous Women in Hunan, China (2017–2018).

Variables	Total (%)	Nulliparous	Multiparous	P-value
	144,845 (100.0 %)	60,686(41.9 %)	84,159(58.1 %)	
Maternal age				0.040
< 25 years	6912(4.8)	5481(9.0)	1431(1.7)	
25 – 29 years	30905 (21.3)	19486(32.1)	11419(13.6)	
30 – 34 years	65177 (45.0)	29086(47.9)	36091(42.9)	
\geq 35 years	41851 (28.9)	6633(10.9)	35218(41.8)	
Marital status				0.035
Single/Divorced/ Widowed	2134(1.5)	1427(2.4)	707(0.8)	
Married/Cohabiting	142711 (98.5)	59259(97.6)	83452(99.2)	
Educational status				0.003
Primary/Illiteracy	1086(0.7)	343(0.6)	743(0.9)	
Secondary	92647 (64.0)	34983(57.6)	57664(68.5)	
Tertiary	51112 (35.3)	25360(41.8)	25752(30.6)	
Gravidity				< 0.001
Nulligravida (O/	40593	40462(66.7)	131(0.2)	
none)	(28.0)			
Primigravida (1	91931	19537(32.2)	72394(86.0)	
pregnancy)	(63.5)			
Multigravida (≥2 pregnancies)	12321(8.5)	687(1.1)	11634(13.8)	
Number of ANC visits				< 0.001
0–3 ANC visits	7697(5.3)	2165(3.6)	5532(6.6)	
4–9 ANC visits	94017 (64.9)	37902(62.5)	56115(66.7)	
≥ 10 ANC visits	43131 (29.8)	20619(34.0)	22512(26.7)	
Place of birth				0.002
Provincial/Municipal	69994	34416(56.7)	35578(42.3)	
hospital	(48.3)			
County-level hospital	74851 (51.7)	26270(43.3)	48581(57.7)	
Mode of Childbirth				< 0.001
Normal vaginal birth/SVD	80686 (55.7)	37747(62.2)	42939(51.0)	
Cesarean section	60226 (41.6)	21608(35.6)	38618(45.9)	
Instrumental/ Assisted childbirth	(41.6) 3933(2.7)	1331(2.2)	2602(3.1)	

ANC: Antenatal Care, SVD: Spontaneous Vaginal Delivery. Significant at $\mathrm{P}<0.05.$




Fig. 1. Incidence of Postpartum Hemorrhage in Nulliparous and Multiparous Women in Hunan, China (2017–2018).

nulliparous and multiparous women. Specifically, forward stepwise logistic regression analysis was used to calculate the adjusted odds ratio (aOR) and 95 % confidence interval(CI). The study adjusted for maternal sociodemographic and obstetric factors (maternal age, marital status, educational status, and gravidity). The entry and removal points were set at 0.10 and 0.15 during the analysis, respectively. A two-sided probability p-value of ≤ 0.05 was considered statistically significant for this study. Also, the receiver operating characteristic curve (ROC curve) was used to examine the predictive performance of the identified influencing factors of PPH. Subgroup analysis using single and combined influencing factors of PPH was performed in the overall study cohort and within the nulliparous and multiparous women's groups. All the statistical analyses were performed using IBM SPSS Statistics Version 26.0 (IBM Corp., Chicago, IL, USA).

3. Results

3.1. Descriptive Statistics

A total of 144,845 postpartum women were included in this study; 60,686(41.9 %) were nulliparous women, and 84,159(58.1 %) were multiparous women. The study included more women (45.0 %) aged 30–34. The majority of the women (98.5 %) were married or cohabiting, most (64.0 %) had secondary school education, and a majority (63.5 %) of the women were primigravida. Furthermore, 64.9 % of the women had 4–9 ANC visitation records, and most (51.7 %) used county-level hospitals as a place of birth. Most (55.7 %) of the women had a normal vaginal delivery (see Table 1).

3.2. Incidence of Postpartum Hemorrhage (PPH)

As in Fig. 1., 2,724 women had PPH (postpartum blood loss \geq 500 ml), giving an overall PPH incidence of 1.9 %. From the subgroup analysis, moderate PPH incidence was 1.3 %, and severe PPH incidence was 0.6 %. Furthermore, 1,259 nulliparous women had PPH, while 1,465 multiparous women had PPH. Nulliparous women had a slightly higher PPH incidence (2.1 %) than multiparous women (1.7 %).

3.3. Univariate analysis on potential influencing factors of PPH

In Table 2, a univariate analysis was performed to assess each independent variable relationship to PPH in the nulliparous and multiparous women's groups. Maternal age, gravidity, ANC visits, the model of birth, types of pregnancy, birth weight, anemia, hepatopathy, blood clot formation disorder, platelet count < 50,000 μ l, puerperal infection, preeclampsia/eclampsia, placenta previa, placenta abruption, soft birth canal avulsion, thrombophlebitis, hysterectomy, general anesthesia used before birth, magnesium sulfate before birth, erythrocyte suspension transfusion before birth, and platelet transfusion were all significantly related to PPH in both nulliparous and multiparous women's groups. However, education level, marital status, place of childbirth, gestational age, and systemic infection had significant relationship to PPH among only the nulliparous women. In contrast, gestational hypertension, HELLP syndrome, and amniotic fluid embolism were significantly related to PPH among only the multiparous women.

3.4. Multivariate analysis on influencing factors of PPH

Furthermore, forward stepwise logistic regression analysis was used to calculate the adjusted odds ratios (aORs) and 95 % confidence intervals for factors influencing PPH. Erythrocyte suspension transfusion before birth was the predominant influencing factor for PPH in the overall study cohort and within the subgroups of nulliparous and multiparous women. Other similar influencing factors of PPH in both nulliparous and multiparous women's groups were low ANC (0–3) visits, anemia, soft-birth canal avulsion, Cesarean-section, placenta abruption,

Table 2

Univariate Analysis Comparing Factors Significantly Associated with Postpartum Hemorrhage between Nulliparous and Multiparous Women in Hunan, China (2017–2018).

Variables	Total	Nulliparous (n	= 60,686)		Multiparous (n $=$ 84,159)		
	n (%)	РРН	No PPH	P-value	РРН	No PPH	P-value
Maternal age				< 0.001			0.01
< 25 years	6912(4.8)	111(8.8)	5370(9.0)		35(2.4)	1396(1.7)	
25 – 29 years	30905(21.3)	359(28.5)	19127(32.2)		191(13.0)	11228(13.6)	
30 – 34 years	65177(45.0)	604(48.0)	28482(47.9)		585(39.9)	35506(42.9)	
> 35 years	41851(28.9)	185(14.7)	6448(10.9)		654(44.6)	34564(41.8)	
Marital status				0.006	,	0.000 ((1000)	0.214
Single/Divorced/Widowed	2134(1.5)	15(1.2)	1412(2.4)	01000	8(0.5)	699(0.8)	0.21
Married/Cohabiting	142711(98.5)	1244(98.8)	58015(97.6)		1457(99.5)	81995(99.2)	
Educational status	112/11(5010)	1211(5010)	00010()/10)	0.004	1107(5510)	01550(5512)	0.700
Primary/Illiteracy	1086(0.7)	5(0.4)	338(0.6)	01001	13(0.9)	730(0.9)	017 0
Secondary	92647(64.0)	671(53.3)	34312(57.7)		989(67.5)	56675(68.5)	
Fertiary	51112(35.3)	583(46.3)	24777(41.7)		463(31.6)	25289(30.6)	
	51112(55.5)	363(40.3)	24///(41./)	0.001	403(31.0)	23269(30.0)	< 0.00
Gravidity	40502(20.0)	700(60.1)	20620(66.2)	0.001	2(0.2)	100(0.0)	< 0.00
Nulligravida (O/none)	40593(28.0)	782(62.1)	39680(66.8)		3(0.2)	128(0.2)	
Primigravida (1 pregnancy)	91931(63.5)	456(36.2)	19081(32.1)		1177(80.3)	71217(86.1)	
Multigravida (≥ 2 pregnancies)	12321(8.5)	21(1.7)	666(1.1)		285(19.5)	11349(13.7)	
Number of ANC visits				< 0.001			< 0.00
0–3 ANC visits	7697(5.3)	17(1.4)	2148(3.6)		61(4.2)	5471(6.6)	
4–9 ANC visits	94017(64.9)	801(63.6)	37101(62.4)		1037(70.8)	55078(66.6)	
\geq 10 ANC visits	43131(29.8)	441(35.0)	20178(34.0)		367(25.1)	22145(26.8)	
Place of birth				< 0.001			0.98
Provincial/Municipal hospital	69994(48.3)	778(61.8)	33638(56.6)		619(42.3)	34959(42.3)	
County-level hospital	74851(51.7)	481(38.2)	25789(43.4)		846(57.7)	47735(57.7)	
Mode of Childbirth				< 0.001			< 0.00
Normal Vaginal delivery/SVD	80686(55.7)	950(75.5)	36797(61.9)		946(64.6)	41993(50.8)	
Cesarean section	60226(41.6)	292(23.2)	21316(35.9)		489(33.4)	38129(46.1)	
Instrumental/Assisted delivery	3933(2.7)	17(1.4)	1314(2.2)		30(2.0)	2572(3.1)	
Gestational age (Weeks)				0.041			0.33
Ferm (37–41 weeks)	131155(90.5)	1169(92.9)	54168(91.2)		1303(88.9)	74515(90.1	
Preterm (<37 weeks)	13513(9.3)	87(6.9)	5186(8.7)		160(10.9)	8080(9.8)	
Post-term (\geq 42 weeks)	177(0.1)	3(0.2)	73(0.1)		2(0.1)	99(0.1)	
	1//(0.1)	3(0.2)	/3(0.1)	< 0.001	2(0.1)	99(0.1)	< 0.00
Fype of pregnancy	141752(97.9)	1188(94.4)	57606(96.9)	<0.001	1410(96.2)	81548(98.6)	< 0.00
Singleton fetus Pregnancy							
Multiple fetus Preg. (≥ 2)	3093(2.1)	71(5.6)	1821(3.1)	.0.001	55(3.8)	1146(1.4)	. 0. 00
Birth weight	10(041(07.0)	1051(05.1)	50000(07.0)	<0.001	1150(00.0)		< 0.00
Normal birth weight (2500-3999 g)	126041(87.0)	1071(85.1)	52222(87.9)		1172(80.0)	71576(86.6)	
Low birth weight (<2500 g)	11133(7.7)	68(5.4)	4662(7.8)		116(7.9)	6287(7.6)	
Large birth weight (\geq 4000 g)	7671(5.3)	120(9.5)	2543(4.3)		177(12.1)	4831(5.8)	
Anemia	40717(28.1)	954(75.8)	15274(25.7)	< 0.001	1097(74.9)	23392(28.3)	< 0.00
Diabetes	15709(10.8)	151(12.0)	6144(10.3)	0.057	174(11.9)	9240(11.2)	0.39
Hepatopathy	3110(2.1)	38(3.0)	1092(1.8)	0.002	49(3.3)	1931(2.3)	0.01
Gestational hypertension	2987(2.1)	33(2.6)	1381(2.3)	0.489	47(3.2)	1526(1.8)	< 0.00
Blood clot formation disorder	51(0.0)	5(0.4)	11(0.0)	< 0.001	16(1.1)	19(0.0)	< 0.00
Low Platelet count < 50,000 µl	42(0.0)	3(0.2)	15(0.0)	< 0.001	6(0.4)	18(0.0)	< 0.00
Systemic infection/Sepsis	2123(1.5)	29(2.3)	898(1.5)	0.023	16(1.1)	1180(1.4)	0.28
HELLP Syndrome	45(0.0)	1(0.1)	14(0.0)	0.212	2(0.1)	28(0.0)	0.03
Puerperal infection	108(0.1	5(0.4)	57(0.1)	0.001	3(0.2)	43(0.1)	0.01
Preeclampsia/Eclampsia	3326(2.3)	50(4.0)	1540(2.6)	0.002	57(3.9)	1679(2.0)	< 0.00
Placenta previa	1652(1.1)	18(1.4)	431(0.7)	0.004	86(5.9)	1117(1.4)	<0.00
Placenta abruption	589(0.4)	13(1.0)	223(0.4)	< 0.001	38(2.6)	315(0.4)	< 0.00
Soft birth canal avulsion	2171(1.5)	95(7.5)	1071(1.8)	< 0.001	71(4.8)	934(1.1)	< 0.00
Amniotic fluid embolism	5(0.0)	0(0.0)	1(0.0)	0.884	1(0.1)	3(0.0)	< 0.00
	12(0.0)						
Thrombophlebitis Hystopotomy		2(0.2)	4(0.0)	< 0.001	1(0.1)	5(0.0)	0.00
Hysterectomy	2265(1.6)	40(3.2)	826(1.4)	< 0.001	44(3.0)	1355(1.6)	< 0.00
General anesthesia used before childbirth	68032(47.0)	471(37.4)	25944(43.7)	< 0.001	615(42.0)	41002(49.6)	< 0.00
Magnesium sulfate used before childbirth	2029(1.4)	30(2.4)	921(1.5)	0.019	42(2.9)	1036(1.3)	< 0.00
Erythrocyte suspension transfusion before childbirth	1027(0.7)	184(14.6)	144(0.2)	< 0.001	298(20.3)	401(0.5)	< 0.00
Platelet transfusion	69(0.0)	8(0.6)	20(0.0)	< 0.001	10(0.7)	31(0.0)	< 0.00

ANC: Antenatal Care, Preg.: Pregnancy, SVD: Spontaneous Vaginal Delivery. Significance at $\mathsf{P} < 0.0.$

general anesthesia administration before birth, low birth weight (<2500 g), and hysterectomy. However, low ANC (0–3) visits [aOR 2.90 (1.65–5.08), $p \le 0.001$], anemia [aOR 8.41(7.34–9.64), $p \le 0.001$], soft birth canal avulsion [aOR 4.01(3.11–5.16), $p \le 0.001$], and erythrocyte suspension transfusion before childbirth [aOR 48.67(36.43–65.04), $p \le 0.001$] had increased odds for PPH among the nulliparous women compared to the multiparous women, while Cesarean section [aOR 5.81 (4.63–7.27), $p \le 0.001$], placenta abruption [aOR 3.62(2.31–5.66), $p \le 0.001$], and general anesthesia administration before birth [aOR 1.63

(1.33–2.01), $p \leq 0.001$] had increased odds for PPH among the multiparous than in the nulliparous women. Additionally, thrombophlebitis [aOR 18.46 (1.67–20.31), p < 0.05] was associated with PPH among only the nulliparous women, while instrument-assisted birth [aOR 1.95(1.16–3.28), p < 0.05] and gestational hypertension [aOR 1.57(1.13–2.19), p < 0.005] were associated with PPH among only the multiparous women (Table 3).

Table 3

Multivariate Logistic Regression Analysis Comparing Influencing Factors of Postpartum Hemorrhage between Nulliparous and Multiparous Women in Hunan, China (2017–2018).

arrow of ANC visits 2.90 (1.65-5.08)*** arrow of ANC visits 0.26 (1.65-5.08)*** 1.85 (1.35-2.53)*** 4-9 ANC visits 0.86 (0.76-0.99) 0.84 (0.74-0.96) 210 ANC visits (Ref.) 1 (ref.) (ref.) Normal vaginal birth/ 1(ref) 1 I(ref.) SVD(Ref.) 1.44 (0.82-2.73) 1.95 (1.16-3.28)* birth 5.02 (4.03-6.2.6)*** 5.81 (4.63-7.27)*** Instrument-assisted 1.49 (0.82-2.73) 1.95 (1.16-3.28)* birth 1.49 (0.82-2.73) 1.95 (1.16-3.28)* Gestational age (ref.) - - - Gestational age (ref.) - - - - Normal birth weight 1.42 (0.98-0.095)* - - - - No (Ref.) 1 (ref.) (ref.) (ref.) - - - - - - - - -	Variables	Nullipa	rous (n = 60,686)	Multipa	rous (n = 84,159)
0-9 ANC visits2.90(1.65-5.08)***1.85(1.35-2.53)***4-9 ANC visits0.86(0.76-0.99)0.84(0.74-0.96)210 ANC visits(1.67)1(1cef.)1(ref.)(ref.)1(ref.)1Mode of Childbirth1(1cef.)1(1cef.)Normal vaginal birth/10(2)(4.03-6.26)***5.02(4.03-7.27)***SvD(Ref.)(4.03-6.26)***1.463-7.27)***(4.63-7.27)***Instrument-assisted1.49(0.82-2.73)1.95(1.16-3.28)*Birth1.49(0.82-2.73)1.95(1.16-3.28)*Birth1.49(0.82-2.73)1.95(1.16-3.28)*Preterm (<37 weeks)		aOR	95 % CI	aOR	95 % CI
0-9 ANC visits2.90(1.65-5.08)***1.85(1.35-2.53)***4-9 ANC visits0.86(0.76-0.99)0.84(0.74-0.96)210 ANC visits(1.67)1(1cef.)1(ref.)(ref.)1(ref.)1Mode of Childbirth1(1cef.)1(1cef.)Normal vaginal birth/10(2)(4.03-6.26)***5.02(4.03-7.27)***SvD(Ref.)(4.03-6.26)***1.463-7.27)***(4.63-7.27)***Instrument-assisted1.49(0.82-2.73)1.95(1.16-3.28)*Birth1.49(0.82-2.73)1.95(1.16-3.28)*Birth1.49(0.82-2.73)1.95(1.16-3.28)*Preterm (<37 weeks)	Number of ANC visits				
> 10 ANC visits (Ref.)1 (ref.)1(ref.)1 (ref.)1(ref.)1(ref.)Nome of Childbirt(ref.)(ref.)(ref.)(ref.)Normal vaginal birth5.02(4.03-6.26)***5.02(1.6-3.28)*Cesarean section birth5.02(4.03-6.26)***5.02(1.6-3.28)*Instrument-assisted1.49(0.82-2.73)1.95(1.16-3.28)*Birth1.49(0.82-2.73)1.95(1.16-3.28)*Gestational age(ref.)(weeks)11(ref.)Pretern (<37 weeks)		2.90	(1.65-5.08)***	1.85	(1.35-2.53)***
Image (ref.) (ref.) (ref.) Mode of Childbirth 1(ref.) 1 (ref.) 1 (ref.) Normal vaginal birth/ SVD(Ref.) 5.02 (4.03-6.26)*** 5.81 (4.63-7.27)*** Instrument-assisted 1.02 (0.82-2.73) 5.81 (1.6-3.28)* birth Gestational age (weeks) 1 1 (ref.) - Cestational age (weeks) 1 1 (ref.) - - (Ref.) 1 1 (ref.) - - - Preterm (<37 weeks)	4–9 ANC visits	0.86	(0.76–0.99)	0.84	(0.74–0.96)
Mode of ChildbirnIrefe Irefe (ref.)Irefe (ref.)Normal vaginal birth/ SVD(K0Iref.)(ref.)(ref.)Cesarean section birth5.02(4.03-6.25)***5.81(4.63-7.27)***Instrument-assisted1.49(0.82-2.73)1.95(1.16-3.28)*birthI(ref.)Gestational age 	≥ 10 ANC visits (Ref.)		1(ref.)		1(ref.)
Normal vaginal birth/ SVDRE1Inef.) (ref.) (ref.)Inef.) (ref.) (ref.)Cesarean section birth Instrument-assisted birth1.49(0.82-2.73)1.95(1.63-7.27)***.Cesarean section birth Instrument-assisted birth1.49(0.82-2.73)1.95(1.16-3.28)*Gestational age (ref.)IIref.)Gestational age (ref.)IIref.)Term (37-41 weeks)1.42(0.99-2.02)Preterm (-242 weeks)0.42(0.99-2.02)Preterm (-242 weeks)0.42(0.99-2.02)Post-term (-242 weeks)0.42(0.99-2.02)Post-term (-242 weeks)0.42(0.99-2.02)ImmediationIref.)Iref.)Iref.)ImmediationIref.)Iref.)Iref.)Iref.)-Laws birth weight0.34(0.28-0.43)***0.44(0.367-0.52)***Laws birth weight0.34(0.28-0.43)***Iref.)Iref.)Laws birth weight0.34(0.28-0.43)***Iref.)Iref.)Laws birth weight0.34(0.28-0.43)***Iref.)Iref.)No (Ref.)0.34(7.34-9.64)***Iref.)Iref.)No (Ref.)1Iref.)Iref.)Iref.)Iref.)No (Ref.)1Iref.)Iref.)Iref.)Iref.)No (Ref.)1Iref.)Iref.)Iref.)Iref.)<		(ref.)		(ref.)	
SVD(Re1)(ref.)(ref.)Cesaran section birth5.02(4.03-6.26)***5.81(4.63-7.27)***Instrument-assided5.02(0.82-2.73)1.01(1.16-3.28)*ibirth(0.82-2.73)(0.81-3.28)*(1.16-3.28)*Gestational ageI(1.66)(weeks)I(1.66)Term (37-41 weeks)1.42(0.99-2.02)Posterm (>242 weeks)0.28(0.08-0.0.95)*Birth weight1.42(0.99-2.02)Posterm (>242 weeks)0.28(0.08-0.0.95)*Birth weight1.41(1ref.)1(1ref.)(2500 399 g) (Ref.)(ref.)(ref.)(1.62-72)**Low birth weight0.34(0.28-0.43)***0.44(0.367-0.52)(<2500 g)		1(1(406)	1	1(40)
Cesarean section birth Instrument-assisted5.02(4.03-6.26)***5.81(4.63-7.27)***Instrument-assisted1.49(0.82-2.73)1.95(1.16-3.28)*birth Gestational age (weeks)11(ref.)Term (37-41 weeks)1.42(0.99-2.02)Post-term (>242 weeks)0.28(0.08-0.05)*Post-term (>242 weeks)1.42(0.99-2.02)Post-term (>242 weeks)0.28(0.08-0.05)*Birth weight1.42(0.79-3.11)***2.09(1-6-2.72)***Normal birth weight(ref.)(ref.)(ref.)(ref.)Large birth weight0.34(0.28-0.43)***0.44(0.367-0.52)(<2500 g)		I(IeI)	1(101.)		1(Iel.)
birth Gesturional age (weeks)I (ref.)IITerm (37-41 weeks)1(ref.)Pretern (<37 weeks)		5.02	(4.03-6.26)***		(4.63-7.27)***
Gestational age (werss)IIIref	Instrument-assisted	1.49	(0.82–2.73)	1.95	(1.16–3.28)*
(weeks)<					
Term (37-41 weeks)1(ref.)(Ref.)(ref.)Preterm (>37 weeks)1.42(0.99-2.02)Post-term (>42 weeks)0.28(0.08-0 0.95)*Birth weight1(ref.)1(ref.)(2500-3999 g) (Ref.)(ref.)(ref.)(ref.)Low birth weight2.08(1.39-3.11)***0.44(0.3670.52)(<2500 g)	-				
(Ref.)(ref.)		1	1(ref)		
Preterm (<37 weeks) 1.42 (0.99-2.02) - - Post-term (>42 weeks) 0.28 (0.08-0.95)* - - Normal birth weight 1 1(ref.) 1 1(ref.) Normal birth weight 2.08 (1.39-3.11)*** 2.09 (1.6-2.72)*** Low birth weight 0.34 (0.28-0.43)*** 0.44 (0.367-0.52) (<2500 g)			1(101.)	_	_
Birth weight11(ref.)11(ref.)Normal birth weight2.08(1.39-3.11)**2.09(1.6-2.72)**Law birth weight2.08(1.39-3.11)**2.09(1.6-2.72)**Large birth weight0.34(0.28-0.43)**0.44(0.367-0.52)(<2500 g)			(0.99–2.02)	-	_
Normal birth weight (2500-3999 g) (Ref.) 1 (ref.) 1 (ref.) 1 (ref.) Low birth weight (\geq 500 g) 0.34 (0.28-0.43)*** 0.44 (0.367-0.52) *** Large birth weight (\geq 4000 g) 0.34 (0.28-0.43)*** 0.44 (0.367-0.52) *** Anemia - - *** Memia - - *** No (Ref.) 1 (1/ref.) 1 1/ref.) No (Ref.) - - 1.57 (1.13-2.19)** No (Ref.) - - 1.07 - Yes - - 1.07 - No (Ref.) - - - - Yes 2.93 (1.46-5.84)** 3.62 (2.31-5.66) *** No (Ref.) 1 (ref.) - - Yes - - - - No (Ref.) 1 (ref.) - - Yes - - - - Yes - -	Post-term (≥42 weeks)	0.28	(0.08–0 0.95)*	-	-
(2500-3999 g) (Ref.) (ref.) (ref.) (ref.) Low birth weight 2.08 (1.39-3.11)*** 2.09 (1.6-2.72)*** Large birth weight 0.34 (0.28-0.43)*** 0.44 (0.367-0.52) Large birth weight 0.34 (0.28-0.43)*** 0.44 (0.367-0.52) Anemia - - - *** Anemia (ref.) 1 (ref.) 1 Yes 8.41 (7.34-9.64)*** 6.78 (5.98-7.69)*** No (Ref.) 1 1(ref.) 1 1(ref.) Yes 8.41 (7.34-9.64)*** 6.78 (5.98-7.69)*** No (Ref.) 1 1(ref.) 1 1(ref.) Yes 8.41 (7.34-9.64)*** 6.78 (7.34-9.19)** No (Ref.) - - 1.1 (ref.) **** Yes 2.93 (1.46-5.84)** 3.62 (2.31-5.66) **** No (Ref.) 1 (ref.) (ref.) **** ****	-				
Low birth weight (<2500 g)	-		1(ref.)		1(ref.)
(<2500 g) $(((()$			(1 20 2 11)***		(1 6 9 79)***
Large birth weight (≥ 4000 g) 0.34 $(0.28-0.43)^{***}$ 0.44 $(0.367-0.52)$ *** Anemia $(-24000$ g) $***$ $***$ Anemia $(-24000$ g) $(-110)^{***}$ $(-110)^{***}$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ No (Ref.) - $ (ref.)$ $(-113)^{-2.19}^{**}$ No (Ref.) - - 1.57 $(1.13)^{-2.19}^{**}$ No (Ref.) - - 1.67 $(-16)^{-10}$ Yes - - $(ref.)$ $(ref.)$ $***$ No (Ref.) 1 $(ref.)$ $(ref.)$ $***$ $***$ No (Ref.) 1 $(ref.)$ $(ref.)$ $***$ No (Ref.) 1 $(ref.)$ $ -$ No (Ref.) <		2.00	(1.39-3.11)	2.09	(1.0-2.72)
24000 g **** Anemia **** Yes 8.41 (7.34-9.64)*** 6.78 (5.98-7.69)*** No (Ref.) 1 1(ref.) 1 1(ref.) hypertension - (ref.) (ref.) (ref.) Yes - - (ref.) (ref.) No (Ref.) - - 1 1(ref.) Placenta abruption - - 1 1(ref.) Yes 2.93 (1.46—5.84)** 3.62 (2.31—5.66) No (Ref.) 1 1(ref.) 1 1(ref.) Yes 2.93 (1.46—5.84)** 3.62 (2.77—4.82) No (Ref.) 1 1(ref.) ref.) **** No (Ref.) 1 1(ref.) 1 1(ref.) Yes 4.01 (3.11—5.16) 3.66 (2.77—4.82) No (Ref.) 1 1(ref.) **** **** No (Ref.) 1 1(ref.) - - Yes 1.8.46 (1.57—20.31)* - -	. 0,	0.34	(0.28-0.43)***	0.44	(0.367-0.52)
Yes 8.41 (7.34-9.64)*** 6.78 (5.98-7.69)*** No (Ref.) 1 1(ref.) 1 1(ref.) Restational (ref.) (ref.) (ref.) hypertension - (ref.) (ref.) Yes - - 1.57 (1.13—2.19)** No (Ref.) - - (ref.) (ref.) Placenta abruption - - (ref.) (ref.) Yes 2.93 (1.46—5.84)** 3.62 (2.31—5.66) No (Ref.) 1 (ref.) iter.) iter.) Yes 2.93 (1.46—5.84)** 3.62 (2.77—4.82) No (Ref.) 1 (ref.) iter.) iter.) Yes 4.01 (3.11—5.16) 3.66 (2.77—4.82) No (Ref.) 1 (ref.) iter.) iter.) Yes 1.0 (ref.) - - No (Ref.) 1 (ref.) - - Yes					
No (Ref.) 1 (ref.) 1 (ref.) (ref.) 1 (ref.) 1 (ref.) (ref.) Gestational hypertension - 1.57 $(1.132.19)^{**}$ Yes - 1 $(1.132.19)^{**}$ No (Ref.) - - 1 $(1.132.19)^{**}$ No (Ref.) - - 1 $(1.132.19)^{**}$ Yes 2.93 $(1.465.84)^{**}$ 3.62 $(2.315.66)$ No (Ref.) 1 $(ref.)$ 1 $(ref.)$ Yes 2.93 $(1.465.84)^{**}$ 3.62 $(2.315.66)$ Soft birth canal avulsion . . $***$ $***$ Yes 4.01 $(3.115.16)$ 3.66 $(2.774.82)$ No (Ref.) 1 $(ref.)$. . Yes 4.01 $(3.15.16)$ 3.66 $(2.774.82)$ No (Ref.) 1 $(ref.)$. . . Yes 1.61 $(ref.)$. . . Yes					
(ref.) (ref.) (ref.) Gestational hypertension - - 1.57 $(1.13-2.19)^{**}$ No (Ref.) - - 1 $(ref.)$ $(ref.)$ Placenta abruption - - $(ref.)$ $(ref.)$ $(ref.)$ Placenta abruption - - $(ref.)$ $(ref.)$ $(ref.)$ Placenta abruption - - $(ref.)$ $(ref.)$ $(ref.)$ Yes 2.93 $(1.46-5.84)^{**}$ 3.62 $(2.31-5.66)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ Yes 2.93 $(1.46-5.84)^{**}$ 3.62 $(2.31-5.66)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ $(ref.)$ Yes 4.01 $(3.11-5.16)$ 3.66 $(2.77-4.82)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ Yes 1.8.46 $(1.67-2.0.31)^*$ $ -$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ $(ref.)$ Yes 2.50 <td></td> <td></td> <td></td> <td></td> <td></td>					
Gestational hypertension - - 1.57 $(1.13 - 2.19)^{**}$ Yes - - 1 $(ref.)$ No (Ref.) - - 1 $(ref.)$ Placenta abruption - - - 1 Yes 2.93 $(1.46 - 5.84)^{**}$ 3.62 $(2.31 - 5.66)$ No (Ref.) 1 $(ref.)$ 1 $(ref.)$ Soft birth canal - - - - avulsion - - - - Yes 4.01 $(3.11 - 5.16)$ 3.66 $(2.77 - 4.82)$ No (Ref.) 1 $(ref.)$ - - Yes 1.63 <td< td=""><td>No (Ref.)</td><td></td><td>1(ref.)</td><td></td><td>1(ref.)</td></td<>	No (Ref.)		1(ref.)		1(ref.)
hypertension	Gestational	(iei.)		(iei.)	
Yes - - 1.57 $(1.13 - 2.19)^{**}$ No (Ref.) - - 1 $(ref.)$ Placenta abruption - - $(ref.)$ $(ref.)$ Yes 2.93 $(1.46 - 5.84)^{**}$ 3.62 $(2.31 - 5.66)$ No (Ref.) 1 $(ref.)$ 1 $(ref.)$ Soft birth canal avulsion - - $(ref.)$ $(ref.)$ Yes 4.01 $(3.11 - 5.16)$ 3.66 $(2.77 - 4.82)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $ref.$ No (Ref.) 1 $(ref.)$ $(ref.)$ $ref.$ No (Ref.) 1 $(ref.)$ $(ref.)$ $-$ No (Ref.) 1 $(ref.)$ $ -$ No (Ref.) 1 $(ref.)$ $ -$ No (Ref.) 1 $(ref.)$ $ -$ Yes 2.50 $(1.67 - 3.75)$ 2.59 $(1.73 - 3.89)$ **** No (ref.) 1 $1(ref.)$ $ref.$ $ref.$ Yes 1.42<					
(ref.) Placenta abruption Yes 2.93 $(1.46-5.84)^{**}$ 3.62 $(2.31-5.66)$ *** No (Ref.) 1 (ref.) $(ref.)$ $(ref.)$ $(ref.)$ Soft birth canal avulsion 1 (ref.) $(ref.)$ $(ref.)$ $(ref.)$ Yes 4.01 $(3.11-5.16)$ *** 3.66 $(2.77-4.82)$ *** No (Ref.) 1 (ref.) $(ref.)$ $(ref.)$ $(ref.)$ Yes 4.01 $(3.11-5.16)$ *** 3.66 $(2.77-4.82)$ *** No (Ref.) 1 (ref.) $(ref.)$ $(ref.)$ $(ref.)$ Yes 1.8.46 $(1.67-20.31)^*$ $ -$ No (Ref.) 1 (ref.) $(1ref.)$ (ref.) $ -$ No (ref.) 1 (ref.) $(1.67-3.75)$ *** 2.59 $(1.73-3.89)$ *** No (ref.) 1 (ref.) $(ref.)$ $(ref.)$ $(ref.)$ Yes 1.42 $(1.191.69)$ *** 1.63 $(1.332.01)$ *** No (Ref.) 1 $(ref.)$ (ref.) $(ref.)$		-	-	1.57	(1.13-2.19)**
Placenta abruption Yes 2.93 $(1.465.84)^{**}$ 3.62 $(2.315.66)_{***}$ No (Ref.) 1 (ref.) 1 1(ref.) $(ref.)$ Soft birth canal avulsion $(ref.)$ 1 1(ref.) 1 Yes 4.01 $(3.115.16)_{***}$ 3.66 $(2.774.82)_{***}$ No (Ref.) 1 $(1ref.)$ 1 $(ref.)$ Yes 4.01 $(1ref.)$ 1 $(ref.)$ No (Ref.) 1 $(1cf.)$ $ -$ No (Ref.) 1.0 $(1cf.)$ $ -$ No (Ref.) 2.50 $(1.673.75)_{***}$ 2.59 $(1.733.89)_{***}$ No (ref.) 1 $(ref.)$ $ref.$ $***$ No (ref.) 1 $(ref.)$ $ref.$ $***$ No (Ref.) 1.42 $(1.191.69)_{***}$ $(1.332.01)_{***}$ Yes 1.42 $(1.191.69)_{***}$ $ref.$ $***$ No (Ref.) 1 $(ref.)$ re	No (Ref.)	-	-		1(ref.)
Yes 2.93 $(1.46-5.84)^{**}$ 3.62 $(2.31-5.66)$ *** No (Ref.) 1 $(ref.)$ 1 $(ref.)$ Soft birth canal avulsion . . . Yes 4.01 $(3.11-5.16)$ *** 3.66 $(2.77-4.82)$ *** No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ Thrombophlebitis 1 $(ref.)$ $(ref.)$ $(ref.)$ Yes 18.46 $(1.67-20.31)^*$ $ -$ No (Ref.) 1 $(ref.)$ $ -$ No (Ref.) 1 $(1.67-3.75)$ 2.59 $(1.73-3.89)$ *** No (ref.) 1 $(ref.)$ $(ref.)$ $ref.$ Yes 2.50 $(1.67-3.75)$ 2.59 $(1.73-3.89)$ *** No (ref.) 1 $(ref.)$ $ref.$ $ref.$ Yes 1.42 $(1.19-1.69)$ 1.63 $(1.33-2.01)$ *** No (ref.) 1 $(ref.)$ $ref.$ $ref.$ Yes 1.42 $(1.19-1.69)$ 1.63 $(1.33-2.01)$ *** </td <td>Dia contra charactica</td> <td></td> <td></td> <td>(ref.)</td> <td></td>	Dia contra charactica			(ref.)	
No (Ref.) 1 (ref.) 1(ref.) 1 (ref.) Soft birth canal avulsion 1 (ref.) (ref.) Yes 4.01 (3.11—5.16) 3.66 (2.77—4.82) No (Ref.) 1 (1cef.) *** *** No (Ref.) 1 (1cef.) (ref.) *** No (Ref.) 1 (1cef.) (ref.) - Yes 18.46 (1.67—20.31)* - - No (Ref.) 1 (ref.) - - No (Ref.) 1 (ref.) - - No (ref.) 1 (ref.) - - Yes 2.50 (1.67—3.75) 2.59 (1.73—3.89) *** *** - - - No (ref.) 1 (ref.) 1 (ref.) Yes 1.42 (1.19—1.69) 1.63 (1.33—2.01) *** 1.42 (ref.) - - Yes 1.42 (ref.) (ref.) *** No (Ref.) 1 (ref.) ***	-	2 03	(1 46_5 84)**	3.62	(2 31_5 66)
(ref.) (ref.) (ref.) Soft birth canal avulsion	165	2.90	(1.10 0.01)	0.02	
Soft birth canal avulsion Ves 4.01 $(3.11 - 5.16)$ *** 3.66 $(2.77 - 4.82)*** No (Ref.) 1 (1cf.) 1 (ref.) No (Ref.) 1 (1cf.) (ref.) Thrombophlebitis - - Yes 18.46 (1.67 - 20.31)^* - No (Ref.) 1 1(ref.) - No (Ref.) 1 1(ref.) - Wes 2.50 (1.67 - 3.75) 2.59 (1.73 - 3.89) No (ref.) 1 1(ref.) ref. *** No (ref.) 1 1(ref.) 1(ref.) ref. Yes 1.42 (1.19 - 1.69) 1.63 (1.33 - 2.01) wath *** *** *** *** No (Ref.) 1 1(ref.) (ref.) *** No (Ref.) 1 1(ref.) *** *** No (Ref.) 1 1(ref.) *** *** No (Ref.) 1 1(ref.) **** ****$	No (Ref.)	1	1(ref.)	1	1(ref.)
avulsion		(ref.)		(ref.)	
Yes 4.01 $(3.11-5.16)$ *** 3.66 $(2.77-4.82)$ *** No (Ref.) 1 1(ref.) 1 1(ref.) Thrombophlebitis - - Yes 18.46 $(1.67-20.31)^*$ - No (Ref.) 1 1(ref.) - Yes 2.50 $(1.67-3.75)$ 2.59 $(1.73-3.89)$ *** No (ref.) 1 1(ref.) 1 1(ref.) Wes 1 1(ref.) 1 1(ref.) Ves 1.42 $(1.19-1.69)$ 1.63 $(1.33-2.01)$ *** No (Ref.) 1 1(ref.) 1 1(ref.) Kes 1.42 $(1.19-1.69)$ 1.63 $(1.33-2.01)$ *** No (Ref.) 1 1(ref.) 1 1(ref.) Wes 1.42 $(1.19-1.69)$ 1.63 $(3.7.2-5.54)$ *** Suspension transfusion before birth 1 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
**** **** **** No (Ref.) 1 1(ref.) 1 (ref.) (ref.) (ref.) Thrombophlebitis - - Yes 18.46 (1.67—20.31)* - - No (Ref.) 1 1(ref.) - - No (Ref.) 1 1(ref.) - - (ref.) (ref.) - - - No (ref.) 1 1(ref.) 1 1(ref.) (ref.) 1 (ref.) (ref.) *** No (ref.) 1 1(ref.) 1 1(ref.) (ref.) 1 (ref.) (ref.) *** Yes 1.42 (1.19—1.69) 1.63 (1.33—2.01) **** No (Ref.) 1 1(ref.) *** *** No (Ref.) 1 1(ref.) 1 1(ref.) *** Frythrocyte suspension *** *** *** Suspension *** *** *** *** Yes 48.67		4.01	(3.11 5.16)	3 66	(277 482)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tes	4.01		3.00	
Thrombophlebitis Yes 18.46 $(1.67-20.31)^*$ $ -$ No (Ref.) 1 $(1ref.)$ $ -$ No (Ref.) 1 $(1ref.)$ $ -$ Hysterectomy 2.50 $(1.67-3.75)$ 2.59 $(1.73-3.89)$ Yes 2.50 $(1.67-3.75)$ 2.59 $(1.73-3.89)$ No (ref.) 1 $(1ref.)$ 1 $(1ref.)$ General anesthesia $(ref.)$ $(ref.)$ $(ref.)$ $(ref.)$ Yes 1.42 $(1.19-1.69)$ 1.63 $(1.33-2.01)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$ Erythrocyte $suspension$ $(ref.)$ $(ref.)$ $(ref.)$ Yes 48.67 $(36.43-65.04)$ 46.58 $(37.72-57.54)$ No (Ref.) 1 $(ref.)$ $(ref.)$ $(ref.)$	No (Ref.)	1	1(ref.)	1	1(ref.)
Yes 18.46 $(1.67-20.31)^*$ - - No (Ref.) 1 $(1cf.)$ - - No (Ref.) 1 $(1cf.)$ - - Hysterectomy		(ref.)		(ref.)	
No (Ref.)1 (ref.)(Iref.) (ref.)- - - -Hysterectomy Yes2.50 $(1.67-3.75)$ ***2.59 $(1.73-3.89)$ ***No (ref.)1 (ref.)1 (ref.) (ref.)1 (ref.)1 (ref.) (ref.)General anesthesia used before birth- ***- (ref.)- (ref.)Yes1.42 $(1.19-1.69)$ ***1.63 $(1.33-2.01)$ ***No (Ref.)1 (ref.)1 (ref.) (ref.)1 (ref.)1 (ref.) (ref.)Erythrocyte suspension transfusion before birth- 36.43-65.04)46.58 46.58 $(37.72-57.54)$ ***No (Ref.)11 (ref.)11 (ref.)	-				
$\begin{array}{c c c c c } (ref.) & & & & & & & & & & & & & & & & & & &$				-	-
Hysterectomy 2.50 (1.673.75) 2.59 (1.733.89) No (ref.) 1 (1cf.) 1 (1crf.) (ref.) (ref.) (ref.) (ref.) General anesthesia used before birth 1 (1cref.) 1 Yes 1.42 (1.191.69) 1.63 (1.332.01) No (Ref.) 1 (ref.) (ref.) (ref.) Erythrocyte suspension transfusion before birth 48.67 (36.4365.04) 46.58 (37.7257.54) Yes 48.67 (36.4365.04) 46.58 (37.7257.54) No (Ref.) 1 1(ref.) 1 1(ref.)	NO (REL)		I(rei.)	-	-
Yes 2.50 $(1.673.75)$ *** 2.59 $(1.733.89)$ *** No (ref.) 1 1(ref.) 1 1(ref.) General anesthesia used before birth (ref.) (ref.) (ref.) Yes 1.42 (1.19169) 1.63 $(1.332.01)$ No (Ref.) 1 1(ref.) 1 1(ref.) Keythrocyte suspension transfusion before birth 1 1(ref.) 1 1(ref.) Yes 48.67 $(36.4365.04)$ *** 46.58 $(37.7257.54)$ No (Ref.) 1 1(ref.) 1 1(ref.)	Hysterectomy	(101.)			
No (ref.) 1 (ref.) 1(ref.) 1 (ref.) 1(ref.) General anesthesia used before birth - - - - Yes 1.42 (1.19—1.69) 1.63 (1.33—2.01) No (Ref.) 1 1(ref.) 1 1(ref.) Korgenspin 1 1(ref.) 1 1(ref.) Brythrocyte suspension transfusion before birth - - - - Yes 48.67 (36.43—65.04) *** 46.58 (37.72—57.54) - No (Ref.) 1 1(ref.) 1 1(ref.) - -		2.50	(1.67—3.75)	2.59	(1.73-3.89)
(ref.) (ref.) General anesthesia used before birth					
General anesthesia used before birth Image: state interval and state	No (ref.)		1(ref.)		1(ref.)
used before birth I.42 (1.19—1.69) I.63 (1.33—2.01) Yes 1 (1cf.) 1 (1cf.) No (Ref.) 1 (1cf.) 1 (1cf.) Erythrocyte ref.) ref.) ref.) ref.) Frythrocyte suspension ref.) ref.) ref.) Yes 48.67 (36.43—65.04) 46.58 (37.72—57.54) No (Ref.) 1 1(ref.) 1 1(ref.)	Conoral anosthesia	(ref.)		(ref.)	
Yes 1.42 (1.19—1.69) *** 1.63 (1.33—2.01) *** No (Ref.) 1 1 (ref.) 1 1 (ref.) Image: Constraint of the second seco					
No (Ref.) 1 (ref.) 1(ref.) 1 (ref.) 1(ref.) Erythrocyte suspension transfusion before birth 3 <td></td> <td>1.42</td> <td>(1.19—1.69)</td> <td>1.63</td> <td>(1.33-2.01)</td>		1.42	(1.19—1.69)	1.63	(1.33-2.01)
(ref.) (ref.) Erythrocyte suspension transfusion before birth (ref.) Yes 48.67 (36.43—65.04) 46.58 (37.72—57.54) No (Ref.) 1 1(ref.) 1 1(ref.)			***		***
Erythrocyte suspension transfusion before birth 48.67 (36.43—65.04) *** 46.58 (37.72—57.54) *** No (Ref.) 1 1(ref.) 1 1(ref.)	No (Ref.)		1(ref.)		1(ref.)
suspension transfusion before birth 48.67 (36.43—65.04) *** 46.58 (37.72—57.54) *** No (Ref.) 1 1(ref.) 1 1(ref.)	Further out	(ref.)		(ref.)	
transfusion before birth 48.67 (36.43—65.04) *** 46.58 (37.72—57.54) *** No (Ref.) 1 1(ref.) 1 1(ref.)					
birth 48.67 (36.43—65.04) 46.58 (37.72—57.54) No (Ref.) 1 1(ref.) 1 1(ref.)					
*** *** No (Ref.) 1 1(ref.) 1 1(ref.)					
No (Ref.) 1 1(ref.) 1 1(ref.)	Yes	48.67		46.58	
	N (D ()				
(101.) (101.)	NO (Ref.)		1(ref.)		I(ref.)
		(iei.)		(161.)	

ANC: Antenatal Care, SVD: Spontaneous Vaginal Delivery, Ref: Reference category. From Anemia to erythrocyte suspension transfusion before birth, each variable is categorized as "Yes and No," and "No" is the reference. Adjusted for maternal sociodemographic and obstetric characteristics (maternal age, marital status, educational status, and gravidity). *** =P \leq 0.001, **=P \leq 0.005, *=P < 0.05.




Fig. 2a. Receiver Operating Characteristic Curve for Predictive Performance of Combined Influencing Factors of Postpartum Hemorrhage among Nulliparous Women in Hunan, China (2017–2018).




Fig. 2b. Receiver Operating Characteristic Curve for Predictive Performance of Combined Influencing Factors of Postpartum Hemorrhage among Multiparous Women in Hunan, China (2017–2018).

3.5. Predictive performance

The ROC curve reflected the model's predictive performance using a single factor and combined influencing factors for PPH in the overall study cohort and within the nulliparous and multiparous subgroups (Appendix Tables A.1 to A.4). In the predictive model for the overall study cohort and within the subgroups, anemia and erythrocyte suspension transfusion before birth were two variables that had the highest AUC from the single factor analysis. The performance of the single-factor analysis was relatively unsatisfactory, with an AUC ranging from 0.50 to 0.75. However, from the combined factors analysis, the AUC for the overall study cohort 0.829(0.821–0.838), p < 0.001], the nulliparous group [0.828(0.815–0.844), p < 0.001] were all satisfactory (Fig. 2a., Fig. 2b., Fig. 2c.A–C).




Fig. 2c. Receiver Operating Characteristic Curve for Predictive Performance of Combined Influencing Factors of Postpartum Hemorrhage among both Nulliparous and Multiparous women in Hunan, China (2017–2018).

Table A1

Adjusted OR and AUC with 95 % CI in the Predictive Model for Combined Influencing Factors of PPH among Pregnant Women in Hunan, China, during 2017–2018 (n = 144.845).

Group	AUC	95 % Confidence Interval		P-value
		Lower	Upper	
Overall study cohort	0.829	0.821	0.838	< 0.001
Nulliparous group	0.828	0.815	0.840	< 0.001
Multiparous group	0.833	0.822	0.844	< 0.001

AUC: Area under the curve, OR: Odd ratio, PPH: Postpartum hemorrhage.

4. Discussion

4.1. PPH incidence

The study assessed the differences in PPH incidence and influencing factors among nulliparous and multiparous women. Multiparous women had a lower PPH incidence of 1.7 % compared to 2.1 % PPH incidence among the nulliparous women. Although there are a few studies reporting PPH incidence among nulliparous women, no study has specifically assessed the incidence of PPH among multiparous women. So, compared to the few nulliparous studies (Bais et al., 2004; Govindappagari et al., 2020) on PPH, the incidence of PPH among nulliparous women in our study is much lower, which is probably because China recently launched a comprehensive health reform system that focuses on expanding primary care capacity, extending and improving obstetric emergency care, and delivering vital public health services to everyone (Meng et al., 2019). Furthermore, compared to multiparous women, the higher incidence of PPH among nulliparous women in our study can partly be explained by the fact that nulliparous women lack previous pregnancy and birthing experiences, have lower awareness about the importance of attending regular prenatal assessments, and have little knowledge about proper nutritional diet and exercise, which can influence the occurrence of PPH. So, healthcare professionals are encouraged to frequently conduct pregnancy-related health education for all women of childbearing age, with particular attention to nulliparous women, for the prevention of pregnancy complications such as PPH.

4.2. Influencing factor of PPH

Our study identified some similar and a few different factors influencing PPH in the nulliparous and multiparous women's groups. Low ANC (0-3) visits had an increased risk for PPH in the nulliparous women than multiparous women. The lower risk for PPH associated with ANC

visits among the multiparous women can be explained by previous pregnancy and birthing experiences. Because multiparous women have prior pregnancy experience, they are more likely to follow antenatal healthcare education than nulliparous women (WHO recommended interventions for improving maternal and newborn health. Geneva: World Health Organization Department of Making Pregnancy Safer;, 2009; WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, Switzerland: World Health Organization;, 2016), which decrease their risk of PPH. Inconsistent with a previous study's (Imai, 2020) finding, our study found that anemia and soft birth canal avulsion have an increased odds for PPH in nulliparous women than in multiparous women. It can partly be explained that because nulliparous women have never been pregnant or have never given birth before, they are more likely to have poor nutritional, iron, and folate supplementation habits, which leads to anemia. Anemia in pregnancy can lead to reduced blood volume and impaired coagulation function, which increases the risk of bleeding after birth. Considering the influence of anemia on PPH, it's crucial to provide health education and support for preventing and controlling anemia in all women's groups. Also, the increased risk of PPH due to soft birth canal avulsion among nulliparous women is because the levator ani muscle (which determines the size and shape of the birth canal) often gets extensively stretched during vaginal delivery, causing an increased risk of unnoticed soft birth canal trauma, mostly in nulliparous women due to the first birthing experience, which increases the risk of PPH (Dietz, 2013). During labor and delivery, clinicians should be more vigilant in detecting soft birth canal trauma for prompt intervention.

Furthermore, erythrocyte suspension transfusion before birth was identified as the predominant influencing factor of PPH in both nulliparous and multiparous women's groups, for the first time. Erythrocyte suspension transfusion before birth was performed due to severe maternal anemia (hemoglobin concentration less than 7 g/dL in pregnancy) and profuse intrapartum bleeding as a result of maternal complications, including placenta previa and abruption. A total of 267 (16.2 %) placenta previa (malposition) and 57 (9.7 %) placenta abruptions were included in the group of erythrocyte suspension transfusions before birth (see appendix Table A.5). Hemoglobin is essential for carrying oxygen and nutrients in the blood, and its deficiency can lead to serious health problems for both the mother and the fetus. Accordingly, severe maternal anemia and placenta abnormalities can increase the risks of fetus's growth restriction, stillbirth, preterm birth, low birth weight, PPH, higher blood transfusion rate, and maternal-neonatal mortality (Shi et al., 2022;5(2):e2147046.; Downes et al., 2017; Jing et al., 2018). Our finding highlights the critical importance of addressing severe maternal anemia and placental abnormalities early during pregnancy to prevent serious health risks to both the mother and the fetus. Consistent with a previous study (Xu et al., 2021), our study found that cesarean section and placenta abruption are associated with an increased risk of PPH among multiparous women than in nulliparous women. It is partly because multiparous women are often of advanced age (>35 years). With advanced age and multiparity, the uterus becomes weaker, contracts poorly after birth, and takes longer to heal, increasing PPH risk (Sauer, 2015). Also, because of their older age, multiparous women are at increased risk for placenta abruption, which is most likely associated with decreased uterine blood flow, uteroplacental hypoperfusion, and placental infarctions leading to PPH (Martinelli et al., 2018; Ananth et al., 1996). Interestingly, our study found that general anesthesia administration before birth has higher odds of PPH among multiparous women than nulliparous women. Our finding is supported by existing research (Magann et al., 2005; Chang et al., 2011; Butwick et al., 2014) reports that general anesthesia administration before delivery can increase the risk of PPH. It is partly because general anesthetics can slow postpartum myometrium contraction, increasing PPH risk (Yoo et al., 2006). The effect is more pronounced in multiparous women, who are often older, than in nulliparous women. It is probably because, with advancement in maternal age, the uterus of women becomes looser over

Table A2

Adjusted OR and AUC with 95 % CI in the Predictive Model for Influencing Factors of PPH among Pregnant Nulliparous and Multiparous Women in Hunan, China, during 2017–2018 (n = 144,845).

Variable	Multivaria	te logistic regression anal	ysis	Single factor analysis in predictive model			
	AOR	95 % CIs	P-value	AUC	95 % CIs	P-value	
Number of ANC				0.502	0.481-0.503	0.150	
0–3 ANC visits	2.15	1.63-2.83	≤ 0.001				
4–9 ANC visits	0.85	0.770.93	≤ 0.001				
\geq 10 ANC visits (Ref.)		Ref.					
Mode of Childbirth				0.571	0.561-0.581	≤ 0.001	
Normal vaginal birth/SVD(Ref.)		Ref.					
Cesarean section	7.82	6.86-8.91	≤ 0.001				
Instrumental/Assisted	1.87	1.26-2.77	0.002				
Gestational age (in weeks)				0.501	0.490-0.512	0.886	
Term (37-41 weeks) (Ref.)		Ref.					
Preterm (<37 weeks)	1.41	1.12	0.003				
Post-term (≥42 weeks)	0.47	0.18-1.20	0.110				
Birth weight				0.500	0.462-0.505	≤ 0.001	
Normal birth weight (2500-3999 g) (Ref.)		Ref.					
Low birth weight (<2500 g)	1.48	1.14	0.003				
Large birth weight (≥4000 g)	0.41	0.36-0.47	\leq 0.001				
Anemia				0.741	0.731-0.750	≤ 0.001	
Yes	7.02	6.39-7.70	≤ 0.001				
No (Ref.)		Ref.					
Gestational hypertension				0.504	0.4930.515	0.425	
Yes	1.49	1.16-1.91	0.002				
No (Ref.)		Ref.					
Placenta abruption				0.507	0.496-0.519	0.181	
Yes	3.02	2.04-4.47	≤ 0.001				
No (Ref.)		Ref.					
Soft birth canal avulsion				0.523	0.512-0.535	≤ 0.001	
Yes	4.15	3.454.99	≤ 0.001				
No (Ref.)		Ref.					
Thrombophlebitis				0.501	0.490-0.511	0.926	
Yes	11.96	1.8178.95	0.010				
No (Ref.)		Ref.					
Hysterectomy				0.508	0.497-5.19	0.165	
Yes	2.87	2.16-3.81	≤ 0.001				
No (Ref.)		Ref.					
General anesthesia used before birth				0.511	0.500-0.522	0.050	
Yes	2.87	2.56-3.22	≤ 0.001				
No (Ref.)		Ref.					
Erythrocyte suspension transfusion before birth				0.604	0.592-0.617	≤ 0.001	
Yes	54.06	46.25-63.19	≤ 0.001				
No (Ref.)							

ANC: Antenatal Care, OR: Odd ratio, AUC: Area under the curve, CI: Confidence Interval, SVD: Spontaneous Vaginal Delivery, Ref.: Reference category, PPH: Postpartum Hemorrhage.

time, decreasing its postpartum contractility potential, which increases the risk of PPH (Sauer, 2015; Martinelli et al., 2018; Ananth et al., 1996). Thrombophlebitis was associated with an increased risk of PPH among the nulliparous women but had no association with PPH among the multiparous women. This is the first study reporting thrombophlebitis as an influencing factor for PPH in nulliparous women. For pregnant women with thrombophlebitis, including deep vein thrombosis (DVT), heparin (such as unfractionated heparin (UFH) and low molecular weight heparin (LMWH)) is used for both treatment and prevention of clot progression to reduce the risk of pulmonary embolism (Bates et al., 2016). However, anticoagulants used in pregnancy can increase the risk of PPH due to their blood-thinning effects, inhibiting thrombus and clot formation (Sirico et al., 2019). Also, though infrequent, thrombophlebitis can increase the risk of PPH due to a few interconnected physiological mechanisms. First, disruption of the normal blood flow through veins due to thrombophlebitis can damage the walls of the veins, especially in cases like septic pelvic thrombophlebitis, increasing the risk of PPH (Shi et al., 2021). Secondly, during pregnancy and postpartum, women's blood is in a hypercoagulable state. This hypercoagulability is protective against excessive bleeding but can increase the risk of thrombophlebitis and complications like diffuse intravascular coagulation, which can increase the risk of PPH (Li et al., 2023). Therefore, it is crucial to closely monitor pregnant women with thrombophlebitis, including DVT, to early identify and treat any

complications that may arise as a result of thrombophlebitis or anticoagulant use. Instrument-assisted birth and gestational hypertension were associated with increased odds of PPH among the multiparous women but had no association with PPH among the nulliparous women. Our finding can partly be explained by the fact that multiparous women are often older, and with older maternal age comes an increased risk of pregnancy complications such as high blood pressure and abnormal fetus size, leading to instrument-assisted birth that increases the risk of PPH (Behrens et al., 2017). Inconsistent with a previous study (Sosa et al., 2009), our study revealed that low birth weight (<2500 g) and hysterectomy are influencing factors that have nearly similar odds of PPH in nulliparous and multiparous women. These findings require further research to understand the mechanisms by which low birth weight and hysterectomy can increase the risk of PPH.

4.3. Risk assessment tools

Risk assessment tools are available to help identify 60–85 % of women who will experience obstetric hemorrhage (Dilla et al., 2013). The ROC curve was used to evaluate the model's accuracy in this study. Single-factor and combined-factor analyses were used to measure how well the model fit. During the single-factor analysis, each identified PPH influencing factor was paired against PPH in the prediction model in the overall study cohort and within the nulliparous and multiparous

Table A3

Adjusted OR and AUC with 95 % CI in the Predictive Model for Influencing Factors of PPH among Pregnant Nulliparous Women in Hunan, China, during 2017–2018 (n = 60686).

Variable	Multivaria	te logistic regression analy	vsis	Single fact	Single factor analysis in predictive model		
	AOR	95 % CIs	P-value	AUC	95 % CIs	P-value	
Number of ANC				0.501	0.472-0.504	0.136	
0–3 ANC visits	2.90	1.655.08	≤ 0.001				
4–9 ANC visits	0.86	0.760.99	0.065				
\geq 10 ANC visits (Ref.)		Ref.					
Mode of Childbirth				0.567	0.552-0.583	≤ 0.001	
Normal vaginal birth/SVD(Ref.)		Ref.					
Cesarean section	5.02	4.036.26	≤ 0.001				
Instrumental/Assisted	1.49	0.82-2.73	0.149				
Gestational age (in weeks)				0.508	0.492-0.524	0.328	
Term (37–41 weeks) (Ref.)		Ref.					
Preterm (<37 weeks)	1.42	0.99-2.02	0.104				
Post-term (≥42 weeks)	0.28	0.080 0.95	0.046				
Birth weight				0.503	0.466-0.507	0.039	
Normal birth weight (2500-3999 g) (Ref.)		Ref.					
Low birth weight (<2500 g)	2.08	1.39-3.11	≤ 0.001				
Large birth weight (\geq 4000 g)	0.34	0.28-0.43	\leq 0.001				
Anemia				0.751	0.737-0.765	≤ 0.001	
Yes	8.41	7.34—9.64	≤ 0.001				
No (Ref.)		Ref.					
Placenta abruption				0.503	0.487-0.519	0.689	
Yes	2.93	1.465.84	≤ 0.002				
No (Ref.)		Ref.					
Soft birth canal avulsion				0.529	0.512-0.546	≤ 0.001	
Yes	4.01	3.115.16	≤ 0.001				
No (Ref.)		Ref.	—				
Thrombophlebitis				0.501	0.485-0.517	0.926	
Yes	18.46	(1.67-20.31)	0.011				
No (Ref.)		Ref.					
Hysterectomy				0.509	0.493-0.525	0.277	
Yes	2.50	1.67-3.75	≤ 0.001				
No (Ref.)		Ref.					
General anesthesia used before birth				0.500	0.453-0.505	≤ 0.001	
Yes	1.42	1.19-1.69	≤ 0.001			_	
No (Ref.)		Ref.	—				
Erythrocyte suspension transfusion before birth				0.604	0.576-0.612	≤ 0.001	
Yes	48.67	36.43-65.04	≤ 0.001				
No (Ref.)		Ref.					

ANC: Antenatal Care, OR: Odd ratio, AUC: Area under the curve, CI: Confidence Interval, SVD: Spontaneous Vaginal Delivery, Ref: Reference category, PPH: Postpartum hemorrhage.

subgroups. From the single-factor analysis, the variables had a relatively unsatisfactory AUC between 0.5 and 0.7 (Appendix Tables A.2 to A.4). When combined-factors analysis was used for the whole study group and the two subgroups of nulliparous and multiparous women, the AUC was greater than 0.8 (Appendix Table A.1). The findings show that single influencing factor is a poor predictor of PPH compared to combined influencing factors. Therefore, more attention should be directed to all women with single or multiple influencing factors of PPH for prompt intervention because PPH may occur in women without even a single influencing factor.

4.4. Strengths and limitation

This study presents several strengths. First, it is the first to compare the incidence and factors influencing PPH between nulliparous and multiparous women, offering novel insights for PPH prevention. Second, its unique random sampling method minimized bias, while the large sample size enhanced the findings' generalizability. Finally, the sequential modeling of many possible factors that affect PPH by stratification in both univariate and multivariate analyses increase the chance of finding new influencing factors of PPH. Also, our study has a few limitations. First, the limitations of a retrospective cohort design apply to this study. Lastly, due to data limitations, the study could not assess certain potential PPH-influencing factors, including assisted reproductive technologies (ART) dietary and behavioral factors that could influence the study conclusion.

5. Conclusion

The incidence of PPH was higher in nulliparous women than multiparous women, but influencing factors varied relatively by parity. The study findings provide new insights for the use of different approaches to PPH prevention for nulliparous and multiparous women in clinical practice to ensure better maternal-child safety.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81172680).

CRediT authorship contribution statement

Prince L. Bestman: Writing – review & editing, Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Musa Nget:** . Edwina M. Kolleh: Writing – review & editing, Methodology, Investigation, Data curation. **Eva Moeng:** . Tesfit Brhane: Writing – review & editing, Visualization, Methodology, Investigation. Jun qun Fang: Writing – review & editing, Visualization, Supervision, Conceptualization. Jiayou Luo: Writing – review & editing, Visualization, Validation, Supervision, Funding acquisition, Conceptualization.

Table A4

Adjusted OR and AUC with 95 % CI in the Predictive Model for Influencing Factors of PPH among Pregnant Multiparous Women in Hunan, China, during 2017–2018 (n = 84,159).

Variable	Multivaria	e logistic regression anal	ysis	Single factor analysis in predictive model			
	AOR	95 % CIs	P-value	AUC	95 % CIs	P-value	
Number of ANC				0.509	0.485-0.513	0.905	
0–3 ANC visits	1.85	1.35-2.53	≤ 0.001				
4–9 ANC visits	0.84	0.74-0.96	0.068				
\geq 10 ANC visits (Ref.)		Ref.					
Mode of Childbirth				0.569	0.5550.584	≤ 0.001	
Normal vaginal birth/SVD(Ref.)		Ref.					
Cesarean section	5.81	4.63-7.27	≤ 0.001				
Instrumental/Assisted	1.95	1.16-3.28	0.041				
Birth weight				0.501	0.449-0.508	\leq 0.001	
Normal birth weight (2500-3999 g) (Ref.)		Ref.					
Low birth weight (<2500 g)	2.09	1.60-2.72	\leq 0.001				
Large birth weight (≥4000 g)	0.44	0.367-0.52	\leq 0.001				
Anemia				0.733	0.720-0.746	\leq 0.001	
Yes	6.78	5.987.69	\leq 0.001				
No (Ref.)		Ref.					
Gestational hypertension				0.507	0.4920.522	0.370	
Yes	1.57	1.13-2.19	0.003				
No (Ref.)		Ref.					
Placenta abruption				0.511	0.4960.526	0.146	
Yes	3.62	2.315.66	\leq 0.001				
No (Ref.)		Ref.					
Soft birth canal avulsion				0.519	0.503-0.534	0.015	
Yes	3.66	2.77-4.82	≤ 0.001				
No (Ref.)		Ref.					
Hysterectomy				0.507	0.492-0.522	0.370	
Yes	2.59	1.73	≤ 0.001				
No (Ref.)		Ref.					
General anesthesia used before birth				0.502	0.447-0.507	\leq 0.001	
Yes	1.63	1.33-2.01	≤ 0.001				
No (Ref.)		Ref.					
Erythrocyte suspension transfusion before birth				0.613	0.596-0.630	\leq 0.001	
Yes	46.58	37.72-57.54	\leq 0.001				
No (Ref.)		Ref.					

ANC: Antenatal Care, AOR: Adjusted odd ratio, AUC: Area under the curve, CI: Confidence Interval, SVD: Spontaneous Vaginal Delivery, Ref: Reference category, PPH: Postpartum Hemorrhage.

Table A5

Incidence of Placental previa and abruption in the group of erythrocyte suspension transfusion before birth among Nulliparous and Multiparous women in Hunan, China, during 2017-2018 (n = 144845).

Variable T	Total	Nulliparous ($n = 60686$)			Multiparous (1				
			Erythrocyt before birt	te suspension transfusion th	P-value		Erythrocyte suspension transfusion before birth		P-value
	n	n(%)	Yes	No		n(%)	Yes	No	
Placenta previa					< 0.001				<0.001
Yes	1652(1.1)	449(0.7)	55(12.2)	394(87.8)		1203(1.4)	212(17.6)	991(82.4)	
No	143193(98.9)	60237(99.3)	273(0.5)	59964(99.5)		82956(98.6)	487(0.6)	82469(99.4)	
Placenta abruption					< 0.001				< 0.001
Yes	589(0.4)	236(0.4)	10(4.2)	226(95.8)		353(0.4)	47(13.3)	306(86.7)	
No	144256(99.6)	60450(99.6)	318(0.5)	60132(99.5)		83806(99.6)	652(0.8)	83154(99.2)	

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

The data that has been used is confidential.

Acknowledgements

We gratefully acknowledge the participating health facilities in

Hunan Province for their invaluable support and cooperation, and we extend special thanks to Yao Zhenzhen for meticulously proofreading our manuscript.

Appendix

References

Ananth, C.V., Wilcox, A.J., Savitz, D.A., Bowes Jr, W.A., Luther, E.R., 1996. Effect of maternal age and parity on the risk of uteroplacental bleeding disorders in pregnancy. Obstet Gynecol. 88 (4 Pt 1), 511–516. https://doi.org/10.1016/0029-7844(96)00236-0.

- International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-682. doi:10.2337/dc09-1848.
- Bais, J.M., Eskes, M., Pel, M., Bonsel, G.J., Bleker, O.P., 2004. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 115 (2), 166–172. https://doi.org/10.1016/j.ejogrb.2003.12.008.
- Bates, S.M., Middeldorp, S., Rodger, M., James, A.H., Greer, I., 2016. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 41 (1), 92–128. https://doi.org/10.1007/s11239-015-1309-0.
- Bates, S.M., Rajasekhar, A., Middeldorp, S., et al., 2018. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2 (22), 3317–3359. https://doi.org/10.1182/bloodadvances.2018024802.
- Behrens, I., Basit, S., Melbye, M., et al., 2017. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 358, j3078 https://doi.org/10.1136/bmj.j3078. Published 2017 Jul 12.
- Brown, M.A., Lindheimer, M.D., de Swiet, M., Van Assche, A., Moutquin, J.M., 2001;20 (1):IX-XIV.. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. https://doi.org/10.1081/PRG-
- 100104165. Butwick, A.J., Carvalho, B., El-Sayed, Y.Y., 2014. Risk factors for obstetric morbidity in patients with uterine atony undergoing caesarean delivery. Br J Anaesth. 113 (4), 661–668. https://doi.org/10.1093/bja/aeu150.
- Chang, C.C., Wang, I.T., Chen, Y.H., Lin, H.C., 2011. Anesthetic management as a risk factor for postpartum hemorrhage after cesarean deliveries. Am J Obstet Gynecol. 205 (5), 462.e1–462.e4627. https://doi.org/10.1016/j.ajog.2011.06.068.
- Devine, P.C., 2009. Obstetric hemorrhage. Semin Perinatol. 33 (2), 76–81. https://doi. org/10.1053/j.semperi.2008.12.004.
- Dietz, H.P., 2013. Pelvic floor trauma in childbirth. Aust N Z J Obstet Gynaecol. 53 (3), 220–230. https://doi.org/10.1111/ajo.12059.
- Dilla, A.J., Waters, J.H., Yazer, M.H., 2013. Clinical validation of risk stratification criteria for peripartum hemorrhage. Obstet Gynecol. 122 (1), 120–126. https://doi. org/10.1097/AOG.0b013e3182941c78.
- Dionne MD, Deneux-Tharaux C, Dupont C, et al. Duration of Expulsive Efforts and Risk of Postpartum Hemorrhage in Nulliparous Women: A Population-Based Study. PLoS One. 2015;10(11):e0142171. Published 2015 Nov 10. doi:10.1371/journal.pone.0142171.
- Downes, K.L., Shenassa, E.D., Grantz, K.L., 2017. Neonatal Outcomes Associated With Placental Abruption. Am J Epidemiol. 186 (12), 1319–1328. https://doi.org/ 10.1093/aie/kwx202.
- Feng, X.L., Zhu, J., Zhang, L., et al., 2010. Socio-economic disparities in maternal mortality in China between 1996 and 2006. BJOG. 117 (12), 1527–1536. https:// doi.org/10.1111/j.1471-0528.2010.02707.x.
- Ford, J.B., Roberts, C.L., Simpson, J.M., Vaughan, J., Cameron, C.A., 2007. Increased postpartum hemorrhage rates in Australia. Int J Gynaecol Obstet. 98 (3), 237–243. https://doi.org/10.1016/j.ijgo.2007.03.011.
- Geller, S.E., Adams, M.G., Kelly, P.J., Kodkany, B.S., Derman, R.J., 2006. Postpartum hemorrhage in resource-poor settings. Int J Gynaecol Obstet. 92 (3), 202–211. https://doi.org/10.1016/j.ijgo.2005.12.009.Govindappagari, S., Moyle, K., Burwick, R.M., 2020. Mild Thrombocytopenia and
- Govindappagari, S., Moyle, K., Burwick, R.M., 2020. Mild Thrombocytopenia and Postpartum Hemorrhage in Nulliparous Women With Term, Singleton. Vertex Deliveries. Obstet Gynecol. 135 (6), 1338–1344. https://doi.org/10.1097/ AOG.000000000003861.
- Hogan, M.C., Foreman, K.J., Naghavi, M., et al., 2010. Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet. 375 (9726), 1609–1623. https://doi.org/10.1016/ S0140-6736(1)06518-1
- Imai, K., 2020. Parity-based assessment of anemia and iron deficiency in pregnant women. Taiwan J Obstet Gynecol. 59 (6), 838–841. https://doi.org/10.1016/j. tjog.2020.09.010.
- Jing L, Wei G, Mengfan S, Yanyan H. Effect of site of placentation on pregnancy outcomes in patients with placenta previa. PLoS One. 2018;13(7):e0200252. Published 2018 Jul 17. doi:10.1371/journal.pone.0200252.
- Khan, K.S., Wojdyla, D., Say, L., Gülmezoglu, A.M., Van Look, P.F., 2006. WHO analysis of causes of maternal death: a systematic review. Lancet. 367 (9516), 1066–1074. https://doi.org/10.1016/S0140-6736(06)68397-9.
- Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9:55. Published 2009 Nov 27. doi:10.1186/1471-2393-9-55.

- Kramer, M.S., Berg, C., Abenhaim, H., et al., 2013. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol. 209 (5), 449.e1–449. e4497. https://doi.org/10.1016/j.ajog.2013.07.007.
- Li S, Gao J, Liu J, et al. Incidence and Risk Factors of Postpartum Hemorrhage in China: A Multicenter Retrospective Study. Front Med (Lausanne). 2021;8:673500. Published 2021 Aug 23. doi:10.3389/fmed.2021.673500.
- Li N, Liu Y, Yun A, Song S. Correlation of Platelet Function with Postpartum Hemorrhage and Venous Thromboembolism in Patients with Gestational Hypertension Complicated with Diabetes [retracted in: Comput Math Methods Med. 2023 Sep 27;2023:9783435]. Comput Math Methods Med. 2022;2022:2423333. Published 2022 Jul 18. doi:10.1155/ 2022/2423333.
- Liu, C.N., Yu, F.B., Xu, Y.Z., et al., 2021;21(1):332.. Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. BMC Pregnancy Childbirth. https://doi.org/10.1186/s12884-021-03818-1. Published 2021 Apr 26.
- Magann, E.F., Evans, S., Hutchinson, M., Collins, R., Lanneau, G., Morrison, J.C., 2005. Postpartum hemorrhage after cesarean delivery: an analysis of risk factors. South Med J. 98 (7), 681–685. https://doi.org/10.1097/01.SMJ.0000163309.53317.B8.
- Magann, E.F., Evans, S., Hutchinson, M., Collins, R., Howard, B.C., Morrison, J.C., 2005. Postpartum hemorrhage after vaginal birth: an analysis of risk factors. South Med J. 98 (4), 419–422. https://doi.org/10.1097/01.SMJ.0000152760.34443.86.
- Martinelli KG, Garcia ÉM, Santos Neto ETD, Gama SGND. Advanced maternal age and its association with placenta praevia and placental abruption: a meta-analysis. Cad Saude Publica. 2018;34(2):e00206116. Published 2018 Feb 19. doi:10.1590/0102-311X00206116.
- McDonnell N, Knight M, Peek MJ, et al. Amniotic fluid embolism: an Australian-New Zealand population-based study. BMC Pregnancy Childbirth. 2015;15:352. Published 2015 Dec 24. doi:10.1186/s12884-015-0792-9.
- Meng Q, Mills A, Wang L, Han Q. What can we learn from China's health system reform?. BMJ. 2019;365:12349. Published 2019 Jun 19. doi:10.1136/bmj.12349.
- Sauer, M.V., 2015. Reproduction at an advanced maternal age and maternal health. Fertil Steril. 103 (5), 1136–1143. https://doi.org/10.1016/j.fertnstert.2015.03.004.
- Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-e333. doi:10.1016/S2214-109X(14) 70227-X.
- Shi Q, Gandi DS, Hua Y, et al. Postpartum septic pelvic thrombophlebitis and ovarian vein thrombosis after caesarean section: a rare case report. BMC Pregnancy Childbirth. 2021; 21(1):561. Published 2021 Aug 17. doi:10.1186/s12884-021-04037-4.
- Shi H, Chen L, Wang Y, et al. Severity of Anemia During Pregnancy and Adverse Maternal and Fetal Outcomes. JAMA Netw Open. 2022;5(2):e2147046. Published 2022 Feb 1. doi:10.1001/jamanetworkopen.2021.47046.
- Sirico, A., Saccone, G., Maruotti, G.M., et al., 2019. Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and metaanalysis. J Matern Fetal Neonatal Med. 32 (11), 1893–1900. https://doi.org/ 10.1080/14767058.2017.1419179.
- Sosa, C.G., Althabe, F., Belizán, J.M., Buekens, P., 2009. Risk factors for postpartum hemorrhage in vaginal deliveries in a Latin-American population. Obstet Gynecol. 113 (6), 1313–1319. https://doi.org/10.1097/AOG.0b013e3181a66b05.
- Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy [published correction appears in Am J Gastroenterol. 2016 Nov;111(11):1668]. Am J Gastroenterol. 2016;111(2):176-196. doi:10.1038/ajg.2015.430.

Wei, Q., Xu, Y., Zhang, L., 2020. Towards a universal definition of postpartum hemorrhage: retrospective analysis of Chinese women after vaginal delivery or cesarean section: A case-control study. Medicine (baltimore). 99 (33), e21714.

- Who, 2009. Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta. World Health Organization, Geneva.
- Who, 2012. Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. World Health Organization, Geneva.
- WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, Switzerland: World Health Organization; 2016.
- WHO recommended interventions for improving maternal and newborn health. Geneva: World Health Organization Department of Making Pregnancy Safer; 2009.
- Xu C, Zhong W, Fu Q, et al. Differential effects of different delivery methods on progression to severe postpartum hemorrhage between Chinese nulliparous and multiparous women: a retrospective cohort study [published correction appears in BMC Pregnancy Childbirth. 2021 Jan 19;21(1):64]. BMC Pregnancy Childbirth. 2020;20(1):660. Published 2020 Oct 31. doi:10.1186/s12884-020-03351-7.
- Xu, C., Fu, Q., Tao, H.B., et al., 2018. Effect of Cesarean Section on the Severity of Postpartum Hemorrhage in Chinese Women: The Shanxi Study. Curr Med Sci. 38 (4), 618–625. https://doi.org/10.1007/s11596-018-1922-1.
- Yoo, K.Y., Lee, J.C., Yoon, M.H., et al., 2006. The effects of volatile anesthetics on spontaneous contractility of isolated human pregnant uterine muscle: a comparison among sevoflurane, desflurane, isoflurane, and halothane. Anesth Analg. 103 (2) https://doi.org/10.1213/01.ane.0000236785.17606.58.